EGFR and neoplasm: CD73/NT5E has previously been reported in LUAD tumours and was demonstrated to have a higher expression in EGFR‐mutant tumours versus those with wildtype EGFR, with a further increase seen upon EGFR‐TKI refractoriness (Ferrara et al.